POM vs AMWL

For growth investors, POMDOCTOR Ltd (POM) is the stronger pick with 12.

4% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). Analysts rate American Well Corporation (AMWL) a "Hold" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, American Well Corporation (AMWL) delivered a total return of -96.

9%, compared to -98. 3% for POMDOCTOR Ltd (POM). Over 10 years, the gap is even starker: POM returned -98. 3% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), POMDOCTOR Ltd (POM) is the lower-risk stock at 1.

11β versus American Well Corporation's 1. 31β — meaning AMWL is approximately 18% more volatile than POM relative to the S&P 500.

By revenue growth (latest reported year), POMDOCTOR Ltd (POM) is pulling ahead at 12.

4% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: American Well Corporation grew EPS 57. 1% year-over-year, compared to 1. 6% for POMDOCTOR Ltd. Over a 3-year CAGR, POM leads at 16. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

American Well Corporation (AMWL) is the more profitable company, earning -38.

4% net margin versus -41. 9% for POMDOCTOR Ltd — meaning it keeps -38. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: POM leads at -7. 5% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — AMWL leads at 53. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, POMDOCTOR Ltd (POM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

11)). Both have compounded well over 10 years (POM: -98. 3%, AMWL: -98. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.